



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>Please see many sheets as necessary</i></p>		Complete if Known	
		Application Number	10/532,067
		Filing Date	April 19, 2005
		First Named Inventor	Sutter
		Art Unit	To Be Assigned
		Examiner Name	To Be Assigned
Sheet	1	of	2
		Attorney Docket Number	
		GRUE-004	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Save as many sheets as necessary.

Sheet

1

of

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
<i>SH</i>		WO 02/24224	03-28-2002	Oxxon Pharmaceines Limited		
		DE 196 40 817 A	05-14-1998	Hermann Bujard Prof Dr		✓

Examiner
Signature

Sharon Kers

Date
Considered

6-20-06

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>				Complete If Known	
				Application Number	10/532,067
				Filing Date	April 19, 2005
				First Named Inventor	Sutter
				Art Unit	To Be Assigned
Examiner Name	To Be Assigned				
Sheet	2	of	2	Attorney Docket Number	GRUE-004

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
Sh		SHUTUNG Y., et al. "Addition of the MSA1 signal and anchor sequences to the malaria merozoite surface antigen 1 C0terminal region enhances immunogenicity when expressed by recombinant vaccinia virus" Vaccine, Butterworth Scientific Guilford, GB, Bd. 15, Nr. 12-13, 1 August 1997, Seiten 1303-1313		
Sh		SCHNEIDER J. et al., "Enhanced Immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus ankara" Nature Medicine, Nature Publishing Co. Bd. 4, NR4, April 1998, 397-402		
Sh		OBER B et al., "Immunogenicity and safety of defective vaccinia virus Lister: Comparison with modified vaccinia virus Ankara" Journal of Virology, Bd. 76, Nr. 15, August 2002, Seiten, 7713-7723		
Sh		GOOD M.F., et al. "Immune effector mechanisms in malaria" Current Opinion in Immunology, Current Biology Ltd., XX, Bd. 11, Nr. 4, August 1999, Seiten 412-419		
		RAMSHAW, I.A. et al. "The prime-boost strategy: exciting prospects for improved vaccination" Immunology Today, Elsevier Publications, Cambridge, GB, Bd. 21, Nr. 4, April 2000, Seiten 163-165		

Examiner Signature	Sharon Heint	Date Considered	6-20-06
--------------------	--------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.